Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$10,000,000.00Target Investment:
$1,000,000.00
Skills
Education
- HB
- Uo
- Uo
Lists including Arjun
Investments
Alterome Therapeutics
Total Funding: $230M
Quanta Therapeutics
Total Funding: $110M
Affini-T Therapeutics
Total Funding: $180M
Centessa Pharmaceuticals
Total Funding: $250M
Scorpion Therapeutics
Total Funding: $420M
Allogene Therapeutics
Total Funding: $410M
Pionyr Immunotherapeutics
Total Funding: $79M
Work Experience
2017
Co-Founder and Managing Director
2017
Vida Ventures is a life sciences investment firm founded in 2017 and manages ~$2B AUM. We are passionate about building and funding breakthroughs in biomedicine. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful impact for patients.
2022
Venture Capital Advisor
2022
Venture Capital Advisors (VCAs) are general partners from VC firms providing HBS/ Harvard students & faculty with fundraising information, and feedback on their idea, business models, and other core aspects of their new ventures.
Member Board Of Directors
2021
Alterome Therapeutics is developing alteration-specific therapeutics for high value oncology targets
2021
Co-Founder and Board Member
2021
Affini-T Therapeutics is developing cell therapies focused on oncogenic drivers for solid tumors
2021
Member Board Of Directors
2021
Centessa Pharmaceuticals is developing medicines focused on rare diseases and immuno-oncology NASDAQ: CNTA Compensation Committee Nom/Gov Committee Audit Committee
2020
Member Board Of Directors
2020
Quanta Therapeutics is developing small molecules to oncogenic drivers Compensation Committee Nom/ Gov Committee
2020
Member Board Of Directors
2020
Scorpion Therapeutics is developing medicines for oncology Compensation Committee, Chair Nom/ Gov Committee
Member Board Of Directors
2017
Pionyr Immunotherapeutics is developing medicines focused on modulating the tumor microenvironment Gilead acquired Pionyr for ~$1.5B total consideration
2019 - 2020
Member Board Of Directors
2019 - 2020
Kinnate Biopharma is developing therapies for BRAF and FGFR driven cancers NASDAQ: KNTE
2018 - 2020
Investor
2018 - 2020
Asklepios Bio develops gene therapies for rare diseases Bayer acquired Ask Bio for a total consideration of ~$4B